Press Release
<p>FERRING PHARMACEUTICALS HONORED BY THE AMERICAN INFERTILITY ASSOCIATION</p>
<p>CONTACT:<br/>
Marilyn Seiger
Kovak-Likly Communications
203-762-8833</p>
<p>NEW YORK - October 24, 2001 – Ferring Pharmaceuticals, an international biopharmaceutical company that specializes in infertility treatments, received a “Family Building Award” from the American Infertility Association (AIA), an education and advocacy organization for women and men concerned about family building. The Award was presented at the AIA’s second annual benefit, the Kokopelli Ball, held on October 4, 2001 at the Pierre Hotel in New York City.</p>
<p>“The American Infertility Association is delighted to present our 2001 Family Building Award to Ferring Pharmaceuticals, who is greatly responsible for decreasing the cost of gonadotropins, thereby increasing the possibility of infertility treatment to more patients,” said Pamela Madsen, executive director of the AIA. Madsen and Karen R. Hammond, M.S.N., C.R.N.P., AIA chair, presented the award to Jason H. Nestor, executive director of sales, and Enyde Polesuk, national field sales director of Ferring Pharmaceuticals.</p>
<p>“We thank the AIA for this esteemed industry award, which recognizes Ferring’s contribution to the treatment of infertility,” said Nestor, executive director of sales. “We like to think of ourselves as a patient advocacy company, providing patients with educational resources, ongoing support and effective, high-quality products at a reasonable price.”</p>
<p>Ferring Pharmaceuticals markets Repronex<sup>®</sup> (menotropins for injection USP), for patients undergoing ovulation induction or in vitro fertilization for infertility. Repronex is the lowest-cost human menopausal gonadotropin* (HMG) and the first HMG approved for subcutaneous administration. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Repronex.</p>
<p>Ferring Pharmaceuticals Inc., headquartered in Tarrytown, NY, is part of the Ferring Group, a privately owned, international biopharmaceutical company that specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 1-888-337-7464 or visit the Ferring Web site at www.ferringusa.com.</p>
<p>The American Infertility Association is a national organization headquartered in New York City that provides education, support and advocacy for women and men facing decisions related to family building, reproductive health, preventive health and menopause. The mission of the AIA is to serve as a lifetime resource that helps people make informed choices about their reproductive status and treatment, and forwards the causes of adoption and reproductive health through advocacy, education, awareness building and research funding. For more information, call 1-888-917-3777.</p>
<p># # # </p>
<p>*based on wholesale acquisition cost.</p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
